Date: 11/10/24

Your Name: Ewan Mackay

Manuscript Title: Patient-Reported Assessments of Chronic Cough in Clinical Trials: Accessory or Primary Endpoints?

Manuscript number (if known): JTD-24-705

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

|   |  | Name all entities with whom you have this relationship or indicate none (add rows as needed) | Specifications/Comments (e.g., if payments were made to you or to your institution) |
|---|--|--|---|
|   |  | Time frame: Since the initial  | planning of the work  |
| 1 | All support for the present manuscript (e.g., funding, | XNone  |   |
|   | provision of study materials,                          |  |   |
|   | medical writing, article                               |  |   |
|   | processing charges, etc.)                              |  |   |
|   | No time limit for this item.                           |  |   |
|   |  |  |   |
|   |  |  |   |
|   |  | Time frame: past   | 36 months   |
| 2 | Grants or contracts from                               | XNone  |   |
|   | any entity (if not indicated                           |  |   |
|   | in item #1 above).                                     |  |   |
| 3 | Royalties or licenses                                  | XNone  |   |
|   |  |  |   |
|   |  |  |   |
| 4 | Consulting fees  | XNone  |   |
|   |  |  |   |
|   |  |  |   |

| 5   | Payment or honoraria for   | XNone                        |               |   |
|-----|--|------------------------------|---------------|---|
|     | lectures, presentations,   |                              |               |   |
|     | speakers bureaus,  |                              |               |   |
|     | manuscript writing or educational events   |                              |               |   |
| 6   | Payment for expert   | X None                       |               |   |
| ١   | testimony  |                              |               | _ |
|     | l cooming the second se |                              |               | _ |
| 7   | Support for attending meetings and/or travel   | XNone                        |               |   |
|     |  |                              |               |   |
|     |  |                              |               |   |
| 8   | Patents planned, issued or   | XNone                        |               |   |
|     | pending  |                              |               |   |
|     |  |                              |               |   |
| 9   | Participation on a Data  | XNone                        |               |   |
|     | Safety Monitoring Board or<br>Advisory Board   |                              |               |   |
| 10  | ·  | X None                       |               |   |
|     | in other board, society,   |                              |               |   |
|     | committee or advocacy  |                              |               |   |
|     | group, paid or unpaid  |                              |               |   |
| 11  | Stock or stock options   | XNone                        |               |   |
|     |  |                              |               |   |
| 12  | Receipt of equipment,  | X None                       |               |   |
|     | materials, drugs, medical  |                              |               | _ |
|     | writing, gifts or other  |                              |               |   |
| 10  | services   |                              |               |   |
| 13  | Other financial or non-<br>financial interests   | XNone                        |               |   |
|     | illialiciai liiterests   |                              |               |   |
|     |  |                              |               |   |
|     |  |                              |               |   |
| Ple | ease summarize the above co  | nflict of interest in the fo | ollowing box: |   |
| Г   |  |                              |               |   |
|     | The author has no conflicts of in  | terest to declare.           |               |   |
|     |  |                              |               |   |

Please place an "X" next to the following statement to indicate your agreement:

 $\underline{X}$  I certify that I have answered every question and have not altered the wording of any of the questions on this form.

Date: 11/10/24

**Your Name: Richard Turner** 

Manuscript Title: Patient-Reported Assessments of Chronic Cough in Clinical Trials: Accessory or Primary Endpoints?

Manuscript number (if known): JTD-24-705

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> manuscript only.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

|   |  | Name all entities with whom you have this relationship or indicate | Specifications/Comments (e.g., if payments were made to you or to your institution) |
|---|--|--|---|
|   |  | none (add rows as needed)  | ,   |
|   |  | Time frame: Since the initial                                      | planning of the work  |
| 1 | All support for the present manuscript (e.g., funding, provision of study materials, | XNone  |   |
|   | medical writing, article   |  |   |
|   | processing charges, etc.)  No time limit for this item.                              |  |   |
|   | to time initial to this term   |  |   |
|   |  | Time frame: past   | 36 months   |
| 2 | Grants or contracts from any entity (if not indicated in item #1 above).             | XNone  |   |
| 3 | Royalties or licenses  | XNone  |   |
|   |  |  |   |
| 4 | Consulting fees  | XNone  |   |
|   |  |  |   |

|      |   |                               |              | _ |
|------|---|-------------------------------|--------------|---|
| 5    | Payment or honoraria for lectures, presentations, | XNone                         |              |   |
|      | speakers bureaus,                                 |                               |              |   |
|      | manuscript writing or                             |                               |              |   |
|      | educational events                                |                               |              |   |
| 6    | Payment for expert                                | XNone                         |              |   |
|      | testimony   |                               |              |   |
|      |   |                               |              |   |
| 7    | Support for attending meetings and/or travel      | XNone                         |              |   |
|      |   |                               |              |   |
|      |   |                               |              |   |
| 8    | Patents planned, issued or                        | XNone                         |              |   |
|      | pending   |                               |              | _ |
| 0    | Participation on a Data                           | V None                        |              |   |
| 9    | Safety Monitoring Board or                        | XNone                         |              |   |
|      | Advisory Board                                    |                               |              |   |
| 10   | Leadership or fiduciary role                      | X None                        |              |   |
|      | in other board, society,                          |                               |              |   |
|      | committee or advocacy                             |                               |              |   |
|      | group, paid or unpaid                             |                               |              |   |
| 11   | Stock or stock options                            | X_None                        |              |   |
|      |   |                               |              |   |
| 12   | Receipt of equipment,                             | X None                        |              |   |
| 12   | materials, drugs, medical                         | XNOTIC                        |              | _ |
|      | writing, gifts or other                           |                               |              | _ |
|      | services  |                               |              |   |
| 13   | Other financial or non-                           | XNone                         |              |   |
|      | financial interests                               |                               |              |   |
|      |   |                               |              |   |
|      |   |                               |              |   |
| Dles | saa augumumagina tha akawa aa                     | uflict of interest in the fel | louring hour |   |
| Piea | ise summarize the above co                        | milict of interest in the fol | iowing box:  |   |
| Т    | he author has no conflicts of in                  | terest to declare             |              |   |
| '    | ne dathor has no connects of in                   | terest to deciare.            |              |   |

Please place an "X" next to the following statement to indicate your agreement:

 $\underline{X}$  I certify that I have answered every question and have not altered the wording of any of the questions on this form.

Date: 11/10/24

Your Name: Peter S P Cho

Manuscript Title: Patient-Reported Assessments of Chronic Cough in Clinical Trials: Accessory or Primary Endpoints?

Manuscript number (if known): JTD-24-705

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

|   |   | Name all entities with<br>whom you have this<br>relationship or indicate<br>none (add rows as<br>needed) | Specifications/Comments (e.g., if payments were made to you or to your institution) |
|---|---|--|---|
| 1 | All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.)  No time limit for this item. | Time frame: Since the initial XNone  | planning of the work  |
|   |   | Time frame: past   |   |
| 2 | Grants or contracts from any entity (if not indicated in item #1 above).  | EPSRC<br>Merck   | PI: outside of submitted work  Co: applicant on ISP outside of submitted work       |
| 3 | Royalties or licenses   | XNone  |   |
| 4 | Consulting fees   | None   |   |

| 5    | Payment or honoraria for  | XNone                           |           |  |  |
|------|---|---------------------------------|-----------|--|--|
|      | lectures, presentations,  |                                 |           |  |  |
|      | speakers bureaus,   |                                 |           |  |  |
|      | manuscript writing or   |                                 |           |  |  |
|      | educational events  |                                 |           |  |  |
| 6    | Payment for expert  | XNone                           |           |  |  |
|      | testimony   |                                 |           |  |  |
|      |   |                                 |           |  |  |
| 7    | Support for attending meetings and/or travel                          | XNone                           |           |  |  |
|      |   |                                 |           |  |  |
|      |   |                                 |           |  |  |
| 8    | Patents planned, issued or  | XNone                           |           |  |  |
|      | pending   |                                 |           |  |  |
|      |   |                                 |           |  |  |
| 9    | Participation on a Data   | XNone                           |           |  |  |
|      | Safety Monitoring Board or  |                                 |           |  |  |
|      | Advisory Board  |                                 |           |  |  |
| 10   | Leadership or fiduciary role  | XNone                           |           |  |  |
|      | in other board, society,  |                                 |           |  |  |
|      | committee or advocacy group, paid or unpaid                           |                                 |           |  |  |
| 11   | Stock or stock options  | XNone                           |           |  |  |
|      |   |                                 |           |  |  |
|      |   |                                 |           |  |  |
| 12   | Receipt of equipment,   | XNone                           |           |  |  |
|      | materials, drugs, medical   |                                 |           |  |  |
|      | writing, gifts or other   |                                 |           |  |  |
| 12   | services  | <u> </u>                        |           |  |  |
| 13   | Other financial or non-<br>financial interests                        | XNone                           |           |  |  |
|      | financial interests   |                                 |           |  |  |
|      |   |                                 |           |  |  |
|      |   |                                 |           |  |  |
| Di - |   | udlist of interest in the fell- | uning how |  |  |
| Piea | Please summarize the above conflict of interest in the following box: |                                 |           |  |  |

| The author reports grants or contracts from EPSRC and Merck. |  |
|--|--|
|  |  |
|  |  |
|  |  |
|  |  |

Please place an "X" next to the following statement to indicate your agreement:

<u>X</u> I certify that I have answered every question and have not altered the wording of any of the questions on this form.

Date: 11/10/24

**Your Name: Surinder Birring** 

Manuscript Title: Patient-Reported Assessments of Chronic Cough in Clinical Trials: Accessory or Primary Endpoints?

Manuscript number (if known): JTD-24-705

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> manuscript only.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

|   |   | Name all entities with whom you have this relationship or indicate none (add rows as needed) | Specifications/Comments (e.g., if payments were made to you or to your institution) |
|---|---|--|---|
|   |   | Time frame: Since the initial  | planning of the work  |
| 1 | All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.)  No time limit for this item. | XNone  |   |
|   |   | Time frame: past   | 36 months   |
| 2 | Grants or contracts from any entity (if not indicated in item #1 above).  | Merck  | To institution  |
| 3 | Royalties or licenses   | LCQ  | Personal  |
| 4 | Consulting fees   | Merck  | Personal  |
|   |   | Bellus   | Personal  |
|   |   | Trevi  | Personal  |

|    |  | Nerre     | Personal |
|----|--|-----------|----------|
|    |  | Nocion    | Personal |
|    |  | Axalbion  | Personal |
|    |  | Genentech | Personal |
| 5  | Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events | XNone     |          |
| 6  | Payment for expert testimony   | XNone     |          |
| 7  | Support for attending meetings and/or travel   | XNone     |          |
| 8  | Patents planned, issued or pending   | XNone     |          |
| 9  | Participation on a Data<br>Safety Monitoring Board or<br>Advisory Board                                      | XNone     |          |
| 10 | Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid            | XNone     |          |
| 11 | Stock or stock options   | XNone     |          |
| 12 | Receipt of equipment,<br>materials, drugs, medical<br>writing, gifts or other<br>services                    | XNone     |          |
| 13 | Other financial or non-<br>financial interests   | XNone     |          |

# Please summarize the above conflict of interest in the following box:

| SB has received grant payments from Merck to institution, and personal consulting fees from Merck, Bellus, | Trevi, |
|--|--------|
| Nerre, Nocion, Axalbion and Genentech, and royalties from LCQ.   |        |

Please place an "X" next to the following statement to indicate your agreement:

X I certify that I have answered every question and have not altered the wording of any of the questions on this form.